Zacks Investment Research upgraded shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a sell rating to a hold rating in a research note published on Saturday morning.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

A number of other research firms also recently commented on NLNK. Cantor Fitzgerald reaffirmed an overweight rating and issued a $32.00 target price (up from $20.00) on shares of NewLink Genetics Corporation in a research report on Saturday, April 22nd. Stifel Nicolaus reaffirmed a buy rating and issued a $26.00 target price on shares of NewLink Genetics Corporation in a research report on Saturday, April 22nd. Jefferies Group LLC increased their target price on shares of NewLink Genetics Corporation from $15.00 to $18.00 and gave the company a hold rating in a research report on Thursday, April 6th. ValuEngine raised shares of NewLink Genetics Corporation from a sell rating to a hold rating in a research report on Friday, May 19th. Finally, Robert W. Baird reaffirmed an outperform rating and issued a $25.00 target price on shares of NewLink Genetics Corporation in a research report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. NewLink Genetics Corporation presently has a consensus rating of Hold and an average price target of $18.17.

Shares of NewLink Genetics Corporation (NASDAQ NLNK) opened at 7.40 on Friday. The stock’s 50 day moving average is $7.20 and its 200 day moving average is $13.88. The firm’s market capitalization is $216.68 million. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.21. The firm had revenue of $10.37 million for the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 52.36%. Equities analysts predict that NewLink Genetics Corporation will post ($3.05) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “NewLink Genetics Corporation (NASDAQ:NLNK) Upgraded at Zacks Investment Research” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/newlink-genetics-corporation-nasdaqnlnk-upgraded-at-zacks-investment-research/1465979.html.

A number of hedge funds have recently modified their holdings of NLNK. Vanguard Group Inc. boosted its stake in shares of NewLink Genetics Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock worth $23,134,000 after buying an additional 51,013 shares in the last quarter. FMR LLC boosted its stake in shares of NewLink Genetics Corporation by 119.3% in the fourth quarter. FMR LLC now owns 904,856 shares of the biotechnology company’s stock worth $9,302,000 after buying an additional 492,330 shares in the last quarter. State Street Corp boosted its stake in shares of NewLink Genetics Corporation by 5.7% in the fourth quarter. State Street Corp now owns 430,428 shares of the biotechnology company’s stock worth $4,422,000 after buying an additional 23,029 shares in the last quarter. Columbus Circle Investors boosted its stake in shares of NewLink Genetics Corporation by 155.6% in the first quarter. Columbus Circle Investors now owns 343,041 shares of the biotechnology company’s stock worth $8,267,000 after buying an additional 208,816 shares in the last quarter. Finally, Driehaus Capital Management LLC acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth $5,127,000. Hedge funds and other institutional investors own 51.25% of the company’s stock.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.